Here are five details.
1. In the first quarter, InVivo experiences a net loss of $4.8 million compared to a $6.4 million net loss in the same period in 2017.
2. Decreases in operating expenses allowed for a smaller net loss. The company reported $2 million in research and development expenses in the first quarter of 2018.
3. At the end of the quarter, InVivo had $11.6 million in cash and cash equivalents on hand.
4. During the first quarter, InVivo named Richard Toselli, MD, its president and CEO. He is a board-certified neurosurgeon.
5. InVivo also entered into a common stock purchase agreement with Lincoln Park Capital Fun to sell up to $15 million in shares of common stock to Lincoln Park.
More articles on devices and implants:
SeaSpine reports $33.2M in 2018 Q1 revenue: 6 things to know
Life Spine launches new SI joint fixation website: 4 highlights
RTI Surgical reports $69.9M in Q1 2018 revenues: 5 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
